- Shares of EnteroMedics (ETRM +45.3%) are holding onto this morning's big gains — and then some.
- Count Northland Capital's Suraj Kalia among those who think the stock has further to run.
- "Based on the current 18-month data, and barring any unforeseen kinks in any subgroup analysis (only top-line data has been released so far), we do not envision a mixed or negative ruling in an FDA panel," Kalia says, referencing the pivotal VBLOC study.
- Northland's target is $7 and although Kalia says that the firm "can articulate on DCF's as to how [the] price target was achieved ... ETRM could now be a good takeout target post-approval."
EnteroMedics may be post-approval takeout target: Northland
Dec 3 2013, 14:27 ET